Cite
HARVARD Citation
Bair, S. et al. (2019). Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis. Oncologist. pp. 955-962. [Online].